Mochi Health Launches Enhanced Online Platform to Support Medical Weight Loss Patients Nationwide
SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) —
Mochi Health, a physician-founded telehealth company delivering medical weight loss care directly to patients, announced today the launch of its newly upgraded online platform. The improvements are designed to streamline patient onboarding, optimize communication with healthcare providers, and expand access to evidence-based obesity care across the United States.
As public interest in medical weight management continues to surge, Mochi Health is responding with scalable, user-centric technology that supports safe and affordable access to GLP-1 medications, personalized nutrition counseling, and long-term metabolic health tracking.
'We've redesigned the platform to make science-backed care easier to access, especially for patients who've historically been underserved,' said a Mochi Health spokesperson. 'This update reflects our commitment to clinical quality and digital innovation.'
Key Platform Enhancements Include: Faster Onboarding Process: Patients can now begin care in as little as 24 hours after sign-up through an improved eligibility screening interface.
Patients can now begin care in as little as 24 hours after sign-up through an improved eligibility screening interface. Telehealth Optimization: Real-time chat and video appointment scheduling enhance the provider-patient experience.
Real-time chat and video appointment scheduling enhance the provider-patient experience. Medication Monitoring: Seamless tracking of GLP-1 prescriptions such as semaglutide and tirzepatide, with built-in refill reminders and dosage review tools.
Seamless tracking of GLP-1 prescriptions such as semaglutide and tirzepatide, with built-in refill reminders and dosage review tools. Insurance Navigation Support: Enhanced tools help patients check coverage eligibility and minimize out-of-pocket costs.
Supporting a Growing Public Health Need
Obesity affects more than 42% of adults in the U.S., yet millions still lack access to affordable, comprehensive care. Mochi Health bridges this gap through board-certified obesity medicine specialists, a fully digital care model, and a mission to make evidence-based treatment options—including weight-loss medications—more accessible.
With this latest platform release, Mochi Health aims to scale its outreach and ensure patients in all 50 states can take control of their health journey from the comfort of their homes.
About Mochi Health
Mochi Health is a physician-led digital health company providing individualized weight loss programs through telemedicine. The company offers GLP-1 prescriptions (where appropriate), lifestyle coaching, and medical supervision tailored to each patient's biology and health history. Headquartered in San Francisco, California, Mochi Health is redefining obesity care with compassion, science, and accessibility.
For more information, visit https://joinmochi.com.
Contact:Mochi Health
Email: [email protected] Phone: +1 (619) 648-1247
Website: https://joinmochi.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
- GLIMPSE-1 model achieves state-of-the-art performance in antibody humanization and optimization, enabling scalable, structure-free biologic design from native human immune sequences ALAMEDA, Calif., June 12, 2025--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. "Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years," said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. "With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines." GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: Best-in-class performance in antibody humanization benchmarks compared to nine leading antibody language models Successful affinity optimization across multiple targets, producing sub-nanomolar variants while addressing developability concerns Creation of highly divergent functional antibody variants with <90% sequence identity to parent sequences Species cross-reactivity engineering across human, cynomolgus monkey, and murine targets Engineering for formulation-preferred parameters such as isoelectric point while maintaining binding affinity GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on Contacts Media Kimberly HaKKH
Associated Press
an hour ago
- Associated Press
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 12, 2025-- Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. 'Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years,' said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. 'With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines.' GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on CONTACT: Media Kimberly Ha KKH Advisors 917-291-5744 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: RESEARCH TECHNOLOGY GENETICS SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE SOURCE: Infinimmune Copyright Business Wire 2025. PUB: 06/12/2025 08:07 AM/DISC: 06/12/2025 08:05 AM
Business Wire
an hour ago
- Business Wire
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
ALAMEDA, Calif.--(BUSINESS WIRE)-- Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. 'Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years,' said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. 'With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines.' GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: Best-in-class performance in antibody humanization benchmarks compared to nine leading antibody language models Successful affinity optimization across multiple targets, producing sub-nanomolar variants while addressing developability concerns Creation of highly divergent functional antibody variants with <90% sequence identity to parent sequences Species cross-reactivity engineering across human, cynomolgus monkey, and murine targets Engineering for formulation-preferred parameters such as isoelectric point while maintaining binding affinity GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune.
